CRISPR Therapy Cuts Triglycerides 63% in Phase 1b Cohort
The experimental CTX310 treatment lowered triglycerides and ANGPTL3 in patients with severe hypertriglyceridemia, based on data from 10 participants.
Makkler Newsroom · Nov 9, 05:36 PM · 1 min read